InflaRx's lead drug candidate, vilobelimab, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including Pyoderma Gangraenosum (PG), a rare ulcerative skin disorder.
InflaRx recently released positive interim results from three cohorts in its’ Phase II clinical study to investigate a potential benefit of vilobelimab for patients suffering from PG. In Q4’21, this study completed its treatment period with the observation period to be completed in the 1H’22.
Phase II results published;
Phase III encouraging topline data
released in Q1 2022
InflaRx's lead drug candidate, vilobelimab, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including critical COVID-19.
The program is being funded by grants from the German Ministry of Research and Education along with the German Ministry of Health.
PD-1 or PD-L1 inhibitor Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)
InflaRx has entered into a clinical collaboration agreement with Merck & Co, Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada) to evaluate the combination of vilobelimab and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with a PD-1 or PD-L1 inhibitor Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC). In June 2021, the first patient was dosed in a Phase IIa clinical study with two vilobelimab arms, including one with KEYTRUDA®.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey, U.S.A, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Developing for optimized use for other
chronic inflammatory indications
IFX-2 is an advancement of vilobelimab technology, in preclinical development. IFX-2 is a highly potent anti-complement C5a antibody with a higher humanization grade and altered pharmacokinetic properties.
IFX-2 was developed to target chronic inflammatory diseases with high unmet medical need. Recent scientific publications suggest a fundamental role of the complement factor C5a for various neutrophil driven diseases but also for the disturbance of the T-cell homeostasis, thereby contributing to mechanisms involved in chronic and autoimmune inflammatory diseases. Therapies blocking the C5a / C5aR axis are believed to induce regulatory T-cell generation and decrease Th17- and Th1- type responses. Thus, a therapeutic anti-C5a approach would be applicable within a large variety of T-cell driven inflammatory diseases.